Back to results
US 2022/0016254 A1Published application
Conjugates of fusion proteins of glp-1 and fgf21
AssigneeBeijing Ql Biopharmaceutical Co., Ltd.
InventorsXinle WU, Haixia ZOU, Yuanyuan ZHANG, Bo WU, Wei GUO
Life of this patent
Estimating the term…
Abstract
The present disclosure provides conjugates of polypeptides comprising GLP-1, polypeptide linker and FGF21. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
Claims31
1-75. (canceled)
A polypeptide conjugate comprising a fusion polypeptide conjugated to at least one clearance reducing moiety (CRM),
- wherein the fusion polypeptide comprises or consists essentially of, from N-terminus to C terminus, a GLP-1, a polypeptide linker and a FGF21;
- wherein the at least one CRM is conjugated to at least one conjugatable residue in the fusion polypeptide;
- and
- wherein the polypeptide linker has a length of at least 0-120 amino acid residues, and
- wherein the fusion polypeptide comprises up to two conjugatable residues.
2 more elements
Dependencies are inferred from the claim text.